Worldwide, over 30% of all deaths are attributable to cardiovascular disease (CVD).1 The increasing incidence and high cost of care of CVDs demands a global approach to prevention, early detection & treatment, and monitoring of disease progression. Used in conjunction with clinical information, cardiac biomarkers are crucial to support rapid and accurate diagnosis, especially in acute cases where every minute counts.2-5
As market leader in cardiac biomarkers,6 Roche offers diagnostic tests for heart failure (HF), acute coronary syndrome (ACS), and atrial fibrillation (AF).